Ainos Reports Second Quarter 2022 Financial Results
Ainos Reports Second Quarter 2022 Financial Results
SAN DIEGO, CA / ACCESSWIRE / August 15, 2022 /
加利福尼亞州聖迭戈/ACCESSWIRE/2022年8月15日/
$Ainos(AIMD.US)$ ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its unaudited financial results for the second quarter ended June 30, 2022.
$Ainos(AIMD.US)$Ainos是一家多元化的醫療科技公司，專注於開發新型的護理點檢測、低劑量幹擾素療法和合成RNA驅動的預防性藥物。該公司今天公佈了截至2022年6月30日的第二季度未經審計的財務業績。
Second Quarter 2022 Financial Highlights
2022年第二季度財務亮點
Revenues were US$636,627 in the second quarter of 2022, up 213.6% from US$202,992 in the same period of 2021.
Gross profit was US$317,664, representing a gross margin of 49.9% in the second quarter of 2022.
2022年第二季度的收入為636,627美元，比2021年同期的202,992美元增長了213.6。
2022年第二季度的毛利為317,664美元，毛利率為49.9%。
Chun-Hsien Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We are pleased to announce our first quarterly results as a Nasdaq-listed company with significant year-over-year revenue growth and promising operational milestones. This has been a momentous year for us, our partners, and our shareholders. Receiving approval for our COVID-19 Antigen Self-Test to be sold in Taiwan and the positive preclinical study results for our VELDONA interferon formulation demonstrates the strength of our product portfolio as we strive to fulfill our mission to develop a telehealth-enabled future for precision medicine. Our Nasdaq uplisting is an exciting new chapter in our development, providing us with wider access to capital, raising our corporate profile, and positioning us to deliver greater and more sustainable value for our shareholders. With our low-cost operations and cutting-edge technology, the building blocks for our future growth as a diversified medtech company are firmly in place."
愛諾士董事局主席兼首席執行官蔡俊賢表示：“我們很高興宣佈作為納斯達克上市公司的首個季度業績，營收較上年同期有顯著增長，並有望實現各項運營里程碑。對於我們、我們的合作伙伴和我們的股東來説，這是重要的一年。我們的新冠肺炎抗原自我檢測獲準在臺灣銷售，我們的VELDONA幹擾素配方的臨牀前研究結果呈陽性，這表明了我們產品組合的實力，因為我們正在努力履行我們的使命，為精確醫學開發一個支持遠程醫療的未來。納斯達克的崛起揭開了我們發展的激動人心的新篇章，為我們提供了更廣泛的資金渠道，提升了我們的企業形象，並使我們定位於為股東提供更大、更可持續的價值。憑藉我們的低成本運營和尖端技術，我們作為一家多元化的醫療科技公司未來增長的基石已經牢牢到位。“
Hui-Lan Wu, Chief Financial Officer of Ainos, commented, "Increased sales of our COVID-19 Antigen Rapid Test Kits during the second quarter drove robust year-over-year 213.6% top-line growth. With the additional capital provided by our recent uplisting, we are well positioned to meet our product development targets, capture emerging market opportunities, and generate long-term growth for our shareholders. Looking ahead, we will continue to commercialize our medical device pipeline while expanding and strengthening our innovative product portfolio."
愛諾斯首席財務官吳慧蘭表示：“第二季度，我們的COVID-19抗原快速檢測試劑盒銷量增加，推動營收同比強勁增長213.6%。隨着我們最近的崛起提供了額外的資本，我們處於有利地位，能夠實現我們的產品開發目標，抓住新興市場機遇，為我們的股東帶來長期增長。展望未來，我們將繼續將我們的醫療器械生產線商業化，同時擴大和加強我們的創新產品組合。”
Second Quarter 2022 Financial Results
2022年第二季度財務業績
Revenues
收入
Revenues increased by 213.6% to US$636,627 in the second quarter of 2022 from US$202,992 in the same period of 2021, mainly driven by the increased product sales of the Ainos COVID-19 Antigen Rapid Test Kits in Taiwan.
收入由2021年同期的202,992美元上升至2022年第二季的636,627美元，增幅達213.6%，主要是由於Ainos CoVID-19抗原快速檢測試劑盒在臺灣的產品銷售增加所致。
Cost of Revenues
收入成本
Cost of revenues was US$318,963 in the second quarter of 2022, compared with US$69,508 in the same period of 2021, mainly driven by the increase in associated cost of product sales of the Ainos COVID-19 Antigen Rapid Test Kits.
2022年第二季度的收入成本為318,963美元，而2021年同期為69,508美元，這主要是由於Ainos COVID-19抗原快速檢測試劑盒的相關產品銷售成本增加所致。
Gross Profit
毛利
Gross profit was US$317,664, representing 49.9% of sales in the second quarter of 2022.
毛利潤為317,664美元，佔2022年第二季度銷售額的49.9%。
Total Operating Expenses
總運營費用
Total operating expenses increased by 163.0% to US$2,261,960 in the second quarter of 2022 from US$860,030 in the same period of 2021, mainly attributable to increased research and development expenses. The increase in research and development expenses reflects the Company's ongoing investments in research and development, in line with its product development plans.
總營運開支由2021年同期的860,030美元上升至2022年第二季的2,261,960美元，增幅達163.0%，主要是由於研發開支增加所致。研究和開發費用的增加反映了公司根據其產品開發計劃對研究和開發進行的持續投資。
Net Loss
淨虧損
Net loss attributable to common stock shareholders was US$1,954,032 in the second quarter of 2022, compared with US$749,774 in the same period of 2021.
2022年第二季度普通股股東應佔淨虧損為1,954,032美元，而2021年同期為749,774美元。
Balance Sheet
資產負債表
As of June 30, 2022, the Company had cash and cash equivalents of US$1,753,877, compared with US$1,751,499 as of December 31, 2021.
截至2022年6月30日，公司的現金及現金等價物為1,753,877美元，而截至2021年12月31日的現金及現金等價物為1,751,499美元。
Recent Developments
最新發展動態
On June 21, 2022, the Company announced it has begun marketing the Ainos COVID-19 Antigen Self-Test Kit under an Emergency Use Authorization that was issued by the Taiwan Food and Drug Administration on June 13, 2022 to Taiwan Carbon Nano Technology Corporation, the manufacturer and product co-developer of the test in conjunction with Ainos. Ainos is the exclusive master sales and marketing agent for the COVID-19 Antigen Self-Test Kit.
2022年6月21日，該公司宣佈，根據臺灣食品藥品監督管理局於2022年6月13日向臺灣碳納米科技公司發出的緊急使用授權，已開始銷售Ainos新冠肺炎抗原自檢試劑盒。臺灣碳納米科技公司是Ainos聯合測試的製造商和產品聯合開發商。艾諾斯是新冠肺炎抗原自檢試劑盒的獨家銷售總代理。
On June 27, 2022, the Company announced the topline results from its COVID-19 antiviral efficacy study in hamsters. The available results show that its low-dose oral interferon alpha formulation, VELDONA, has a protective effect on lungs infected with the SARS-CoV-2 virus by regulating the immune response, thus expediting recovery of infected animals. The Company is preparing application documents for U.S. FDA Phase 2/3 clinical trials.
2022年6月27日，該公司公佈了其新冠肺炎對倉鼠的抗病毒療效研究結果。現有結果表明，其低劑量口服幹擾素α製劑VELDONA通過調節免疫反應，對感染SARS-CoV-2病毒的肺部具有保護作用，從而加快受感染動物的康復。該公司正在準備美國FDA第2/3期臨牀試驗的申請文件。
On August 12, 2022, the Company announced the closing of its previously announced underwritten public offering of 780,000 units at a public offering price of $4.25 per unit. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $4.25. The common stock and warrants were immediately separable and were issued separately. The common stock and warrants began trading on the Nasdaq Capital Market on August 9, 2022, under the symbols "AIMD" and "AIMDW," respectively. Ainos received gross proceeds of approximately $3.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses.
2022年8月12日，公司宣佈結束此前宣佈的78萬個單位的包銷公開發行，公開發行價為每單位4.25美元。此次發行的每個單位包括一股普通股和一股認股權證，以4.25美元的行使價購買一股普通股。普通股和認股權證可以立即分開，並單獨發行。該普通股和權證於2022年8月9日在納斯達克資本市場開始交易，代碼分別為AIMD和AIMDW。在扣除承銷折扣和佣金以及其他估計的發行費用之前，Ainos獲得了約330萬美元的毛收入。
About Ainos, Inc.
關於Ainos公司
Headquartered in San Diego, California, Ainos, Inc. (f/k/a Amarillo Biosciences, Inc.) is a diversified medtech company engaged in developing innovative medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. In addition to its proprietary therapeutics using low-dose non-injectable interferon, Ainos is committed to developing a comprehensive healthcare business portfolio encompassing medical devices and consumer healthcare products. While prioritizing the commercialization of medical devices as part of its diversification strategy, Ainos has also expanded its product portfolio to include Volatile Organic Compounds (VOC) and COVID-19 POCTs. Leveraging its patents related to VOC technologies and three issued patents for COVID-19 POCT products, the Company seeks to expedite the commercialization of its medical device pipeline, beginning with Ainos-branded COVID-19 POCT product candidates.
總部設在加利福尼亞州聖地亞哥的Ainos，Inc.(法國/法國/a Amarillo生物科學公司)是一家多元化的醫療科技公司，致力於開發創新的醫療技術，用於護理點檢測和針對各種疾病適應症的安全和新穎的醫療治療。除了使用低劑量非注射幹擾素的專利療法外，Ainos還致力於開發涵蓋醫療設備和消費者保健產品的全面醫療保健業務組合。在將醫療器械商業化作為其多元化戰略的一部分作為優先事項的同時，Ainos還擴大了其產品組合，包括揮發性有機化合物(VOC)和新冠肺炎POCT。利用其與VOC技術相關的專利和三項已頒發的新冠肺炎POCT產品專利，該公司尋求加快其醫療器械生產線的商業化進程，首先是Ainos品牌的新冠肺炎POCT候選產品。
Forward-Looking Statements
前瞻性陳述
This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict," "project," 'target," "future," "seek," "likely," "strategy," "may," "should," "will," and similar references to future periods. Forward-looking statements are based only on our current beliefs, expectations, and assumptions. Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements.
本新聞稿包含符合1995年美國私人證券訴訟改革法安全港條款的“前瞻性陳述”。前瞻性陳述可以通過諸如“預期”、“相信”、“估計”、“預期”、“打算”、“計劃”、“預測”、“項目”、“目標”、“未來”、“尋求”、“可能”、“戰略”、“可能”、“應該”、“將會”以及對未來時期的類似提法來識別。前瞻性陳述僅基於我們當前的信念、預期和假設。前瞻性陳述會受到固有的不確定性、風險和環境變化的影響，這些不確定性、風險和變化很難預測，其中許多是我們無法控制的。我們的實際結果可能與前瞻性陳述中指出的大不相同。
Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others, the following: the cost of production and sales potential of the planned drug treatments announced in this press release; the impact of final approvals from the U.S. Food and Drug Administration (the "FDA") or other regulatory bodies for the planned drug treatments including the availability of emergency use authorization; the Company's limited cash and history of losses; the Company's ability to achieve profitability; intense competition and rapidly advancing technology in the Company's industry that may outpace its technology; customer demand for the products and services the Company develops; the impact of competitive or alternative products, technologies and pricing; the Company's ability to manufacture any products it develops; general economic conditions and events and the impact they may have on the Company and its potential customers, including but not limited to the impact of Covid-19; the Company's ability to obtain adequate financing in the future; the impact of promulgation and implementation of regulations by the World Health Organization, the FDA and by other governmental authorities with functions similar to those of the FDA on the Company's operations and technologies; lawsuits and other claims by third parties or investigations by various regulatory agencies governing the Company's operations; the Company's ability to secure regulatory approvals for its products; and our success in managing the risks involved in the foregoing items. Readers should also review the risks and uncertainties listed in our Annual Report on Form 10-K for the year ended December 31, 2021 and other reports we file with the U.S. Securities and Exchange Commission.
可能導致我們的實際結果與前瞻性陳述中顯示的結果大不相同的重要因素包括但不限於：本新聞稿中宣佈的計劃藥物治療的生產成本和銷售潛力；美國食品和藥物管理局(FDA)或其他監管機構對計劃藥物治療的最終批准的影響，包括緊急使用授權的可用性；公司有限的現金和歷史虧損；公司實現盈利的能力；公司行業的激烈競爭和快速進步的技術可能超過其技術；客户對公司開發的產品和服務的需求；競爭性或替代產品、技術和定價的影響；公司生產其開發的任何產品的能力；總體經濟狀況和事件及其可能對公司及其潛在客户造成的影響，包括但不限於“新冠肺炎”的影響；公司未來獲得充足資金的能力；世界衞生組織、食品和藥物管理局以及其他職能類似於食品和藥物管理局的政府機構頒佈和實施法規對公司業務和技術的影響；第三方的訴訟和其他索賠或管理公司運營的各種監管機構的調查；公司確保其產品獲得監管部門批准的能力；以及我們成功地管理上述項目中涉及的風險。讀者還應查閲我們截至2021年12月31日的Form 10-K年度報告以及我們提交給美國證券交易委員會的其他報告中列出的風險和不確定性。
Any forward-looking statement made by us in this press release speaks only as of the date on which such statement is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
我們在本新聞稿中所作的任何前瞻性聲明僅限於該聲明發表之日。我們沒有義務公開更新任何可能不時作出的前瞻性陳述，無論是書面的還是口頭的，無論是新信息、未來發展還是其他情況。
Investor Relations Contact
ICR, LLC
Robin Yang
Tel: +1 646-224-6971
Email: Ainos.IR@icrinc.com
投資者關係聯繫人
ICR，LLC
楊彥宏
電話：+1646-224-6971
電子郵件：Ainos.IR@icrinc.com
Ainos, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
Ainos公司
簡明綜合 營運説明書
(未經審計)
| Three months ended June 30, | Six months ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
Revenues |
$ | 636,627 | $ | 202,992 | $ | 723,828 | $ | 205,113 | ||||||||
Cost of revenues |
(318,963 | ) | (69,508 | ) | (360,042 | ) | (70,757 | ) | ||||||||
Gross profit |
317,664 | 133,484 | 363,786 | 134,356 | ||||||||||||
Operating expenses |
||||||||||||||||
Research and development expenses |
1,634,856 | - | 3,212,310 | - | ||||||||||||
Selling, general and administrative expenses |
627,104 | 860,030 | 1,178,834 | 1,383,011 | ||||||||||||
Total operating expenses |
2,261,960 | 860,030 | 4,391,144 | 1,383,011 | ||||||||||||
Operating loss |
(1,944,296 | ) | (726,546 | ) | (4,027,358 | ) | (1,248,655 | ) | ||||||||
Non-operating income and expenses, net |
||||||||||||||||
Loss on sale of fixed assets |
- | (2,247 | ) | - | (2,247 | ) | ||||||||||
Interest expense, net |
(18,796 | ) | (20,981 | ) | (35,483 | ) | (32,879 | ) | ||||||||
Other income, net |
9,060 | - | 8,914 | - | ||||||||||||
Total non-operating income and expenses, net |
(9,736 | ) | (23,228 | ) | (26,569 | ) | (35,126 | ) | ||||||||
Net loss |
(1,954,032 | ) | (749,774 | ) | (4,053,927 | ) | (1,283,781 | ) | ||||||||
Basic and diluted net loss per average share available to common shareholders |
$ | (0.01 | ) | $ | (0.01 | ) | $ | (0.03 | ) | $ | (0.02 | ) | ||||
Weighted average common shares outstanding - basic and diluted |
144,379,308 | 124,644,759 | 144,379,308 | 83,583,583 | ||||||||||||
| 截至6月30日的三個月， | 截至6月30日的六個月， | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
收入 |
$ | 636,627 | $ | 202,992 | $ | 723,828 | $ | 205,113 | ||||||||
收入成本 |
(318,963 | ) | (69,508 | ) | (360,042 | ) | (70,757 | ) | ||||||||
毛利 |
317,664 | 133,484 | 363,786 | 134,356 | ||||||||||||
運營費用 |
||||||||||||||||
研發費用 |
1,634,856 | - | 3,212,310 | - | ||||||||||||
銷售、一般和行政費用 |
627,104 | 860,030 | 1,178,834 | 1,383,011 | ||||||||||||
總運營費用 |
2,261,960 | 860,030 | 4,391,144 | 1,383,011 | ||||||||||||
營業虧損 |
(1,944,296 | ) | (726,546 | ) | (4,027,358 | ) | (1,248,655 | ) | ||||||||
營業外收入和費用，淨額 |
||||||||||||||||
固定資產銷售損失 |
- | (2,247 | ) | - | (2,247 | ) | ||||||||||
利息支出，淨額 |
(18,796 | ) | (20,981 | ) | (35,483 | ) | (32,879 | ) | ||||||||
其他收入，淨額 |
9,060 | - | 8,914 | - | ||||||||||||
營業外收支合計(淨額) |
(9,736 | ) | (23,228 | ) | (26,569 | ) | (35,126 | ) | ||||||||
淨虧損 |
(1,954,032 | ) | (749,774 | ) | (4,053,927 | ) | (1,283,781 | ) | ||||||||
普通股股東每股基本和稀釋後每股淨虧損 |
$ | (0.01 | ) | $ | (0.01 | ) | $ | (0.03 | ) | $ | (0.02 | ) | ||||
加權平均已發行普通股-基本普通股和稀釋普通股 |
144,379,308 | 124,644,759 | 144,379,308 | 83,583,583 | ||||||||||||
Ainos, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
Ainos公司
簡明綜合資產負債表
(未經審計)
| June 30, | December 31, | |||||||
| 2022 | 2021 | |||||||
Assets |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 1,753,877 | $ | 1,751,499 | ||||
Inventory |
670,507 | - | ||||||
Other current assets |
1,274,512 | 466,198 | ||||||
Total current assets |
3,698,896 | 2,217,697 | ||||||
Intangible assets, net |
35,086,424 | 37,329,191 | ||||||
Property and equipment, net |
1,503,025 | 1,187,702 | ||||||
Other assets |
124,697 | 87,571 | ||||||
Total assets |
$ | 40,413,042 | $ | 40,822,161 | ||||
Liabilities and Stockholders' Equity |
||||||||
Current liabilities: |
||||||||
Convertible notes payable |
$ | 3,376,526 | $ | 3,376,526 | ||||
Notes payable |
1,013,405 | 213,405 | ||||||
Accrued expenses and others current liabilities |
2,598,468 | 1,004,868 | ||||||
Payables - related party |
- | 26,000,000 | ||||||
Total current liabilities |
6,988,399 | 30,594,799 | ||||||
Long term liabilities: |
||||||||
Convertible notes payable - noncurrent |
27,400,000 | - | ||||||
Operating lease liabilities - noncurrent |
18,323 | 30,255 | ||||||
Total long term liabilities |
27,418,323 | 30,255 | ||||||
Total liabilities |
34,406,722 | 30,625,054 | ||||||
Stockholders' equity |
||||||||
Preferred stock, $0.01 par value; 10,000,000 shares |
||||||||
authorized; none issued |
||||||||
Common stock, $0.01 par value; 300,000,000 shares |
||||||||
authorized as of June 30, 2022 and December 31, |
||||||||
2021; 144,379,308 shares issued and outstanding as |
||||||||
of June 30, 2022 and December 31, 2021 |
1,443,793 | 1,443,793 | ||||||
Additional paid-in capital |
18,943,316 | 18,856,430 | ||||||
Accumulated deficit |
(14,162,843 | ) | (10,108,916 | ) | ||||
Translation adjustment |
(217,946 | ) | 5,800 | |||||
Total stockholders' equity |
6,006,320 | 10,197,107 | ||||||
Total liabilities and stockholders' equity |
$ | 40,413,042 | $ | 40,822,161 | ||||
| 6月30日， | 十二月三十一日， | |||||||
| 2022 | 2021 | |||||||
資產 |
||||||||
流動資產： |
||||||||
現金和現金等價物 |
$ | 1,753,877 | $ | 1,751,499 | ||||
庫存 |
670,507 | - | ||||||
其他流動資產 |
1,274,512 | 466,198 | ||||||
流動資產總額 |
3,698,896 | 2,217,697 | ||||||
無形資產，淨額 |
35,086,424 | 37,329,191 | ||||||
財產和設備，淨額 |
1,503,025 | 1,187,702 | ||||||
其他資產 |
124,697 | 87,571 | ||||||
總資產 |
$ | 40,413,042 | $ | 40,822,161 | ||||
負債與股東權益 |
||||||||
流動負債： |
||||||||
可轉換應付票據 |
$ | 3,376,526 | $ | 3,376,526 | ||||
應付票據 |
1,013,405 | 213,405 | ||||||
應計費用和其他流動負債 |
2,598,468 | 1,004,868 | ||||||
應付款關聯方 |
- | 26,000,000 | ||||||
流動負債總額 |
6,988,399 | 30,594,799 | ||||||
長期負債： |
||||||||
可轉換應付票據-非流動票據 |
27,400,000 | - | ||||||
經營租賃負債--非流動負債 |
18,323 | 30,255 | ||||||
長期負債總額 |
27,418,323 | 30,255 | ||||||
總負債 |
34,406,722 | 30,625,054 | ||||||
股東權益 |
||||||||
優先股，面值0.01美元；1000萬股 |
||||||||
已授權；未頒發 |
||||||||
普通股，面值0.01美元；300,000,000股 |
||||||||
自2022年6月30日和12月31日起授權， |
||||||||
2021年；已發行和已發行的144,379,308股 |
||||||||
2022年6月30日和2021年12月31日 |
1,443,793 | 1,443,793 | ||||||
額外實收資本 |
18,943,316 | 18,856,430 | ||||||
累計赤字 |
(14,162,843 | ) | (10,108,916 | ) | ||||
翻譯調整 |
(217,946 | ) | 5,800 | |||||
股東權益總額 |
6,006,320 | 10,197,107 | ||||||
總負債和股東權益 |
$ | 40,413,042 | $ | 40,822,161 | ||||
SOURCE: Ainos, Inc.
資料來源：Ainos公司
View source version on accesswire.com:
在accesswire.com上查看源代碼版本：